Huntington National Bank’s Allogene Therapeutics ALLO Stock Holding History

Huntington National Bank’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2	Hold	1	–	–	﹤0.01%	4018
2025 Q4	$1	Hold	1	–	–	﹤0.01%	3976
2025 Q3	$1	Sell	1 -734	-100%	-$875	﹤0.01%	4005
2025 Q2	$830	Buy	735 +225	+44%	+$299	﹤0.01%	2365
2025 Q1	$744	Buy	510 +59	+13%	+$111	﹤0.01%	2413
2024 Q4	$961	Buy	451 +2	+0.4%	+$5	﹤0.01%	2392
2024 Q3	$1.26K	Sell	449 -245	-35%	-$653	﹤0.01%	2347
2024 Q2	$1.62K	Buy	694 +274	+65%	+$808	﹤0.01%	2220
2024 Q1	$1.88K	Buy	420 +419	+41,900%	+$1.75K	﹤0.01%	2149
2023 Q4	$3	Buy	+1	New	+$3	﹤0.01%	3656

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Huntington National Bank's ALLO Position: Q1 2026 in Review

Huntington National Bank held its Allogene Therapeutics (ALLO) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #4018.

Huntington National Bank first reported a position in ALLO in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.88K in Q1 2024. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

Huntington National Bank held 1 share of Allogene Therapeutics worth $2 as of Q1 2026.
Huntington National Bank left its Allogene Therapeutics share count unchanged in Q1 2026.
Allogene Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #4018 holding.
Huntington National Bank first reported a position in Allogene Therapeutics in Q4 2023 and has held it in 10 quarters since.
Huntington National Bank's Allogene Therapeutics position peaked at $1.88K in Q1 2024.
208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.